In the latest instalments of the Novartis sponsored DIAbetes Experts onLine (DIAL) webinar series, Professor Emeritus David Matthews, Professor Stefano del Prato, Professor Michael Stumvoll and Dr Païvi M. Paldánius discuss the key findings of the ground-breaking VERIFY trial and share their ideas about how these results might influence the way in which we treat early type 2 diabetes in the future.
DIAL Webinar 2019 – Professor Michael Stumvoll: Is diabetes progression inevitable, is it predictable and is it modifiable?
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with content provided by Novartis Pharma AG. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Time2DoMore is a trademark owned by Novartis Pharma AG. Following codes supersede any other material reference number appearing on the assets: GLEM/GAL/0072, 75, 79, 84, 99. Diabetes Clinical Trials: Date of preparation August 2020 GLEM/GAL/0115 and December 2020 FUSE code: 19416. Hypertension Guidelines Slide Deck - FUSE MLR number: 111312.